CTC in Lung Caner Patients With Bone Metastases

Not Applicable

• Conditions: Lung Cancer; Bone Metastases; Single Cell Sequencing Technology

• Registration Number: NCT04568291
• Lead Sponsor: Shanghai 6th People's Hospital

Brief Summary

1. Evaluate the feasibility of single cell sequencing technology based on three-dimensional bionic capture network;

2. To build a risk prediction model of bone related events based on single cell sequencing;

3. To verify the risk prediction model of bone related events by single cell sequencing;

4. To verify the comprehensive treatment of non-small cell lung cancer ( NSCLC) bone metastases.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-03-06
• Study First Submitted QC: 2020-09-23
• Study First Posted: 2020-09-29
• Study Start: 2020-10-01
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-09
• Last Update Posted: 2021-08-12
• Primary Completion: 2022-03-31
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

1. age 18-75 years
2. pathology-proven diagnosis of lung cancer and radiographical/pathological evidence of BM
3. no previous treatment for BM
4. good general condition (Eastern Cooperative Oncology Group, ECOG Performance scores: 0-2) with an estimated survival time > 3 months.

Exclusion Criteria

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
SREs（Skeletal related events）	1 year	occurance of SREs，including bone pain, pathological fractures, spinal cord compression, hypercalcemia, and the need for surgery or radiotherapy

Trial Locations

Locations (1)

Shanghai Sixth People'S Hospital; 🇨🇳 Shanghai, Other (Non U.s.), China